WO2012124982A3 - 장용코팅된 경구용 제제 - Google Patents

장용코팅된 경구용 제제 Download PDF

Info

Publication number
WO2012124982A3
WO2012124982A3 PCT/KR2012/001846 KR2012001846W WO2012124982A3 WO 2012124982 A3 WO2012124982 A3 WO 2012124982A3 KR 2012001846 W KR2012001846 W KR 2012001846W WO 2012124982 A3 WO2012124982 A3 WO 2012124982A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral preparation
enteric coating
relates
present
zoledronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/001846
Other languages
English (en)
French (fr)
Other versions
WO2012124982A2 (ko
Inventor
이재걸
전호성
김진모
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyundai Pharm Co Ltd
Original Assignee
Hyundai Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyundai Pharm Co Ltd filed Critical Hyundai Pharm Co Ltd
Publication of WO2012124982A2 publication Critical patent/WO2012124982A2/ko
Publication of WO2012124982A3 publication Critical patent/WO2012124982A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 장내 손상을 감소시키면서도 생체이용률이 개선된 졸레드론산 함유 경구 제제에 관한 것으로, 보다 구체적으로, 졸레드론산 및 약학적으로 허용되는 이의 염을 포함하고 코어의 pH가 3.5 내지 7인 장용코팅된 경구용 제제에 관한 것이다.
PCT/KR2012/001846 2011-03-16 2012-03-14 장용코팅된 경구용 제제 Ceased WO2012124982A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110023362A KR20120105738A (ko) 2011-03-16 2011-03-16 장용코팅된 경구용 제제
KR10-2011-0023362 2011-03-16

Publications (2)

Publication Number Publication Date
WO2012124982A2 WO2012124982A2 (ko) 2012-09-20
WO2012124982A3 true WO2012124982A3 (ko) 2012-11-08

Family

ID=46831213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001846 Ceased WO2012124982A2 (ko) 2011-03-16 2012-03-14 장용코팅된 경구용 제제

Country Status (2)

Country Link
KR (1) KR20120105738A (ko)
WO (1) WO2012124982A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180053384A (ko) * 2015-09-18 2018-05-21 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009785A1 (en) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
WO2000061111A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
US6676965B1 (en) * 1999-10-20 2004-01-13 U&I Pharmaceuticals Ltd. Enteric coated formulation for bisphosphonic acids and salts thereof
US20050260262A1 (en) * 2004-05-24 2005-11-24 The Procter & Gamble Company Dosage forms of bisphosphonates
KR100631873B1 (ko) * 2004-07-30 2006-10-09 주식회사 유유 생체이용율이 증진된 알렌드론산 제제
US20070134319A1 (en) * 2003-12-23 2007-06-14 Novartis Ag Pharmaceutical formulations of bisphosphonates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009785A1 (en) * 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
WO2000061111A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
US6676965B1 (en) * 1999-10-20 2004-01-13 U&I Pharmaceuticals Ltd. Enteric coated formulation for bisphosphonic acids and salts thereof
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
US20070134319A1 (en) * 2003-12-23 2007-06-14 Novartis Ag Pharmaceutical formulations of bisphosphonates
US20050260262A1 (en) * 2004-05-24 2005-11-24 The Procter & Gamble Company Dosage forms of bisphosphonates
KR100631873B1 (ko) * 2004-07-30 2006-10-09 주식회사 유유 생체이용율이 증진된 알렌드론산 제제

Also Published As

Publication number Publication date
KR20120105738A (ko) 2012-09-26
WO2012124982A2 (ko) 2012-09-20

Similar Documents

Publication Publication Date Title
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
UA105229C2 (uk) Фармацевтичний склад
WO2013082345A8 (en) Aryl dihydropyridinones and piperidinones as mgat2 inhibitors
WO2010092090A3 (en) Novel salts of sitagliptin
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
EP2621284A4 (en) Method for preparation of an aqueous glyphosate concentrate
WO2014041565A3 (en) Improved process for preparation of vilanterol and intermediates thereof
WO2012056458A3 (en) Intermediate compounds and process for the preparation of fingolimod
WO2014064255A3 (en) Capsules
WO2012074830A3 (en) Modified release tranexamic acid formulation
WO2009117381A3 (en) Preparation of montelukast and its salts
ZA201107412B (en) Methods for the preparation of [2-8,9-dioxo2,6-diazabicyclo[5.2.0]non-1(1)-en-2-yl)ethyl]phosphonic acid and precursors thereof
WO2008049922A3 (en) A new process for the preparation of montelukast
UA106386C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
IL225557A (en) Preparation Method (3s, 3s) 4,4'-Disulfandylbis (3-Aminobutane 1 - Sulfonic Acid)
WO2012112841A3 (en) [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation
BRPI1012007A2 (pt) "método para a preparação de ácido 2-ceto-carboxílico"
WO2012018791A3 (en) Preparation of prasugrel hydrochloride
WO2012014052A3 (en) Novel coated extended release pharmaceutical compositions containing paliperidone
WO2011136513A3 (ko) 디히드록시벤조산 유도체를 포함하는 골이식용 또는 골충진용 조성물
WO2010134048A3 (en) Topical retinoid solutions
HK1216721A1 (zh) 治疗肝脏疾病或病状的用途和方法
IL225680A0 (en) Process for preparing 3-(6-amino-pyridin-3-yl)2-acrylic acid derivatives
WO2011018801A3 (en) Solid oral dosage form of ziprasidone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12757638

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12757638

Country of ref document: EP

Kind code of ref document: A2